Melanoma - Current and Future Players
Summary
GlobalData has released its pharma report, “Melanoma - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Melanoma Market. The report identifies and analyses the key companies shaping and driving the global Melanoma market. The report provides insight into the competitive Melanoma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Scope
- Investigation of current and future market competition for Melanoma
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Melanoma sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving Melanoma market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Melanoma market landscape? Identify, understand and capitalize
Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 Catalyst 5
2.2 Related Reports 6
2.3 Upcoming Related Reports 6
3 Market Outlook 7
3.1 Global Markets 7
3.1.1 Forecast 7
3.1.2 Drivers and Barriers - Global Issues 11
4 Current and Future Players 14
4.1 Overview 14
4.2 Trends in Corporate Strategy 17
4.3 Company Profiles 18
4.3.1 Bristol-Myers Squibb 18
4.3.2 Novartis 21
4.3.3 Roche 24
4.3.4 Merck 27
5 Appendix 31
5.1 Bibliography 31
5.2 Abbreviations 58
5.3 Methodology 63
5.4 Forecasting Methodology 63
5.4.1 Diagnosed Melanoma Patients 63
5.4.2 Percent Drug-Treated Patients 64
5.4.3 Drugs Included in Each Therapeutic Class 64
5.4.4 Launch and Patent Expiry Dates 65
5.4.5 General Pricing Assumptions 66
5.4.6 Average Body Weight and Surface Area Across the 8MM 67
5.4.7 Individual Drug Assumptions 68
5.4.8 Generic Erosion 82
5.4.9 Pricing of Pipeline Agents 82
5.5 Primary Research - KOLs Interviewed for this Report 84
5.6 Primary Research - Prescriber Survey 87
5.7 About the Authors 88
5.7.1 Analyst 88
5.7.2 Therapy Area Director 88
5.7.3 Epidemiologist 89
5.7.4 Global Head of Healthcare 89
5.8 About GlobalData 90
5.9 Disclaimer 90
List Of Tables
1.1 List of Tables
Table 1: Global Sales Forecast ($m) for Melanoma, 2013-2023 9
Table 2: Melanoma Market - Drivers and Barriers, 2015 11
Table 3: Key Companies in the Melanoma Market in the 8MM, 2013-2023 15
Table 4: BMS’ Melanoma Portfolio Assessment, 2015 20
Table 5: Novartis’ Melanoma Portfolio Assessment, 2015 23
Table 6: Roche’s Melanoma Portfolio Assessment, 2015 26
Table 7: Merck’s Melanoma Portfolio Assessment, 2015 29
Table 8: Key Launch Dates 65
Table 9: Key Patent Expiries 66
Table 10 Average Body Weight and Surface Area Across the 8MM 67
Table 11: High-Prescribing Physicians Surveyed by Country 87
List Of Figures
1.2 List of Figures
Figure 1: Global Sales for Melanoma by Region, 2013-2023 10
Figure 2: Global Sales of Branded Products for Melanoma by Company, 2013-2023 16
Figure 3: Company Portfolio Gap Analysis in Melanoma, 2013-2023 17
Figure 4: Bristol-Myers Squibb SWOT Analysis in Melanoma, 2013-2023 21
Figure 5: Novartis SWOT Analysis in Melanoma, 2013-2023 24
Figure 6: Roche SWOT Analysis in Melanoma, 2013-2023 27
Figure 7: Merck SWOT Analysis in Melanoma, 2013-2023 30
Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 Catalyst 5
2.2 Related Reports 6
2.3 Upcoming Related Reports 6
3 Market Outlook 7
3.1 Global Markets 7
3.1.1 Forecast 7
3.1.2 Drivers and Barriers - Global Issues 11
4 Current and Future Players 14
4.1 Overview 14
4.2 Trends in Corporate Strategy 17
4.3 Company Profiles 18
4.3.1 Bristol-Myers Squibb 18
4.3.2 Novartis 21
4.3.3 Roche 24
4.3.4 Merck 27
5 Appendix 31
5.1 Bibliography 31
5.2 Abbreviations 58
5.3 Methodology 63
5.4 Forecasting Methodology 63
5.4.1 Diagnosed Melanoma Patients 63
5.4.2 Percent Drug-Treated Patients 64
5.4.3 Drugs Included in Each Therapeutic Class 64
5.4.4 Launch and Patent Expiry Dates 65
5.4.5 General Pricing Assumptions 66
5.4.6 Average Body Weight and Surface Area Across the 8MM 67
5.4.7 Individual Drug Assumptions 68
5.4.8 Generic Erosion 82
5.4.9 Pricing of Pipeline Agents 82
5.5 Primary Research - KOLs Interviewed for this Report 84
5.6 Primary Research - Prescriber Survey 87
5.7 About the Authors 88
5.7.1 Analyst 88
5.7.2 Therapy Area Director 88
5.7.3 Epidemiologist 89
5.7.4 Global Head of Healthcare 89
5.8 About GlobalData 90
5.9 Disclaimer 90
List Of Tables
1.1 List of Tables
Table 1: Global Sales Forecast ($m) for Melanoma, 2013-2023 9
Table 2: Melanoma Market - Drivers and Barriers, 2015 11
Table 3: Key Companies in the Melanoma Market in the 8MM, 2013-2023 15
Table 4: BMS’ Melanoma Portfolio Assessment, 2015 20
Table 5: Novartis’ Melanoma Portfolio Assessment, 2015 23
Table 6: Roche’s Melanoma Portfolio Assessment, 2015 26
Table 7: Merck’s Melanoma Portfolio Assessment, 2015 29
Table 8: Key Launch Dates 65
Table 9: Key Patent Expiries 66
Table 10 Average Body Weight and Surface Area Across the 8MM 67
Table 11: High-Prescribing Physicians Surveyed by Country 87
List Of Figures
1.2 List of Figures
Figure 1: Global Sales for Melanoma by Region, 2013-2023 10
Figure 2: Global Sales of Branded Products for Melanoma by Company, 2013-2023 16
Figure 3: Company Portfolio Gap Analysis in Melanoma, 2013-2023 17
Figure 4: Bristol-Myers Squibb SWOT Analysis in Melanoma, 2013-2023 21
Figure 5: Novartis SWOT Analysis in Melanoma, 2013-2023 24
Figure 6: Roche SWOT Analysis in Melanoma, 2013-2023 27
Figure 7: Merck SWOT Analysis in Melanoma, 2013-2023 30
